| Trial ID: | L7300 |
| Source ID: | NCT06107153
|
| Associated Drug: |
Insulin Glargine 100 Unt/Ml Pen Injector [Lantus]
|
| Title: |
Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type2diabetes
|
| Interventions: |
DRUG: Insulin Glargine 100 UNT/ML Pen Injector [Lantus]|DRUG: Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg|DRUG: Pioglitazone 30mg
|
| Outcome Measures: |
Primary: Hemoglobin A1c less than 7%, Percentage of patients with hemoglobin A1c of less than 7%, three months|Hemoglobin A1c less than 7%, Percentage of patients with hemoglobin A1c of less than 7%, six months|Hemoglobin A1c less than 7%, Percentage of patients with hemoglobin A1c of less than 7%, twelve months|Change in hemoglobin A1c, mean change in hemoglobin A1c, three months|Change in hemoglobin A1c, mean change in hemoglobin A1c, six months|Change in hemoglobin A1c, mean change in hemoglobin A1c, twelve months | Secondary: Hypoglycemia, Prevalence of capillary blood glucose less than 70 mg/dl by serial monitoring using home glucometer., two weeks
|
| Sponsor/Collaborators: |
Sponsor: University of Basrah
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
243
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2023-11-01
|
| Completion Date: |
2024-11-01
|
| Results First Posted: |
|
| Last Update Posted: |
2025-03-30
|
| Locations: |
Faiha Specialized Diabetes, Endocrine, and Metabolism Center, Basrah, 61001, Iraq
|
| URL: |
https://clinicaltrials.gov/show/NCT06107153
|
